Sign in: Staff/Students
Efforts to develop novel antibiotics are hampered by a number of scientific and regulatory hurdles that cannot be easily tackled by any individual organisation
The University of Liverpool and the Royal Liverpool University Hospital are part of a large European and pharmaceutical partnership to develop new antibiotic treatments.
The Combatting Bacterial Resistance in Europe – Molecules Against Gram-Negative Infections (COMBACTE-MAGNET), project is part of the Innovative Medicines Initiative (IMI), bringing together 33 European academic partners and five pharmaceuticals in research activities to prevent and treat infections that have become resistant to antibiotics.
Antimicrobial resistance (AMR) is a growing problem worldwide, and with few new drugs making it to the market, there is an urgent need for new medicines to manage infections caused by resistant pathogens. Most problematic is the rapid emergence and dissemination of multidrug resistant (MDR) bacteria.
Efforts to develop novel antibiotics are hampered by a number of scientific and regulatory hurdles that cannot be easily tackled by any individual organisation working alone.
The Liverpool team will conduct the first-in-human clinical trials and identify the optimal dosage for patients with life threatening infection for which there are currently severely limited treatment options.
Professor William Hope, from the University’s Institute of Translational Medicine, said: “We have developed the necessary infrastructure and skills that are required for the accelerated development of new antibiotics with activity against drug resistant bacteria.
“The IMI award builds on an existing research theme within the Department of Molecular and Clinical Pharmacology for the development of new drugs for bad bugs.”
Richard Fitzgerald, consultant physician at the Royal Liverpool University Hospital, said: “We are uniquely placed to work together to deliver this important project. The combination of the Clinical Research Unit at the Royal Liverpool and the Antimicrobial Pharmacodynamics & Therapeutics Laboratory at the University means that Liverpool can directly contribute to the development of new drugs that are urgently required for the NHS.”
The COMBACTE-MAGNET project will develop new treatment options for patients with life-threatening infections due to bacterial infections that are resistant to current antibiotics.
You must be logged in to post a comment.
All recent news
Lateral flow tests detect most people at risk of transmitting Covid-19
Free digital skills training for Liverpool students
Social disadvantage in the UK has a lasting impact on childhood asthma
Win a year’s tuition fees with Santander Universities UK
How to share your feedback with us – Student Feedback Hub
Professor Eithne Costello from @LivUni on the link between Type 2 Diabetes and Pancreatic Cancer #ITVTonight at 8pm.
Professor Chris Holloran of The University Of Liverpool (@LivUni) explains the importance of diagnosing Pancreatic Cancer early.
You can watch the full episode on #ITVTonight at 8pm
Researchers from @LivCancerRes feature in a new @ITVTonight film about #PancreaticCancer.
Profs Chris Halloran & Eithne Costello discuss the importance of early detection & the research taking place to help to improve outcomes.
📺 Watch 'Britain's Hidden Killer' on ITV at 8pm.